STRYKER WKN: 864952 ISIN: US8636671013 Kürzel: SYK Forum: Aktien Thema: Hauptdiskussion

20%

Sinnlose Frage

Wieviel % steigt die Rendite jährlich hier

👳

Ab wann?

Stryker Non-GAAP EPS of $2.14 beats by $0.13, revenue of $4.8B beats by $240M https://seekingalpha.com/news/3962930-stryker-non-gaap-eps-of-2_14-beats-0_13-revenue-of-4_8b-beats-240m • Stryker press release (NYSE:SYK): Q1 Non-GAAP EPS of $2.14 beats by $0.13. • Revenue of $4.8B (+11.8% Y/Y) beats by $240M. • Organic net sales increased 13.6% in the quarter including 12.9% from increased unit volume and 0.7% from higher prices. MedSurg and Neurotechnology net sales of $2.7 billion increased 11.0% in the quarter and 13.1% in constant currency. Organic net sales increased 12.4% in the quarter including 10.5% from increased unit volume and 1.9% from higher prices. Orthopaedics and Spine net sales of $2.1 billion increased 12.7% in the quarter and 15.1% in constant currency. Organic net sales increased 15.2% in the quarter including 16.0% from increased unit volume partially offset by 0.8% from lower prices. • Expect full year 2023 organic net sales growth to be in the range of 8.0% to 9.0% and expect adjusted net earnings per diluted share to be in the range of $10.05 to $10.25 vs. $10.00 consensus

https://investors.stryker.com/press-releases/news-details/2023/Stryker-reports-first-quarter-2023-operating-results/default.aspx

Läuft und läuft …..

Bin heute raus. Vielleicht zu früh, aber bei dem Wahnsinnrun ist die Bewertung mittlerweile in absurden Sphären angekommen^^ Bei einem deutlichen Rücksetzer bin ich wieder dabei

Was denn hier schon wieder los 👌👌👌

Stryker’s Q Guidance System for cranial applications receives FDA clearance Cranial Guidance Software offers surgeons robust imaging and guidance during cranial procedures https://www.businesswire.com/news/home/20230217005102/en/Stryker%E2%80%99s-Q-Guidance-System-for-cranial-applications-receives-FDA-clearance

Neues ath 😎

👌🏼

Stryker: EPS übertrifft Schätzungen um 0,16$ - Umsatz besser als erwartet https://m.de.investing.com/news/stock-market-news/stryker-eps-ubertrifft-schatzungen--um-016--umsatz-besser-als-erwartet-2358495

Stryker launches Citrefix™ Suture Anchor System, featuring award-winning Citregen biomaterial designed to support bone regeneration and the natural healing process https://www.businesswire.com/news/home/20221213005214/en/Stryker-launches-Citrefix%E2%84%A2-Suture-Anchor-System-featuring-award-winning-Citregen-biomaterial-designed-to-support-bone-regeneration-and-the-natural-healing-process

Dividende wird um 7,9% auf 0,75$ je Quartal erhöht